Huntington's Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2030

Huntington’s Disease Treatment Market Overview Huntington’s Disease Treatment Market is expected to reach USD 373.31 Million rise steadily at a CAGR of 19.1% during forecast period of 2022-2030.This rise is due to high RandD speculations for new product improvement, research collaboration, and the high HD burden in European countries. Huntington’s disease is an infrequent inherited neurodegenerative disease that affects various generations. The impact of this disease is high when the age is between 30 and 50, hampering their ability to work, care for families, and eventually complete daily tasks. The generality differs by more than ten-fold between geographical areas, which can be associated with differences in case ascertainments and diagnostic criteria. As a result, the generality of enlarged replications in the general population may be larger than expected. The Asian population has continuously had a lower generality, while Europe, North America, and Australia have a higher generality.

Segmentation:

Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. On basis of drug type the Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Huntington’s Disease Treatment Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of traumatic brain injury market.  The European Huntington’s Disease Treatment Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The Huntington’s Disease Treatment Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The huntington’s disease treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

Some of the key players in the Huntington’s Disease Treatment Market are Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.

Regional Market Summary

Global Huntington’s Disease Treatment Market Share (%), by Region, 2017

Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon

Geographically, the America holds the highest market share for huntington’s disease treatment market and the reason being many market players are engaged in development of new drug product innovation. According to the survey carried out by one of the University of Sheffield, the estimated prevalence of huntington’s disease in North America, North Western Europe and Australia ranges from 5.96 to 13.7 cases per 100 000 population.

Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of targeted population, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 

The prevalence of huntington’s disease is significantly lower in Asian populations compared to Western Europe, North America and Australia.

The market in the Middle East & Africa is likely to account for the smallest share of the global huntington’s disease treatment.

Huntington’s Disease Treatment Market by Drug Type:

•      Tetrabenazine


•      Deutetrabenazine


•      Selective Serotonin Reuptake Inhibitor (SSRI)


•      Chlorpromazine


•      Haloperidol


•      Risperidone


•      Olanzapine


•      Clozapine


•      Other

Huntington’s Disease Treatment Market, by Treatment:

•      Symptomatic Therapy


•      Disease-Modifying Therapy

Huntington’s Disease Treatment Market, by End-Users:

•       Hospital


•       Clinics


•       Online Pharmacies


•       Retail Pharmacies


•       Others

Huntington’s Disease Treatment Market, by Region:

• 
  Americas
  
  
  
  • 
     North America
    
    
    
    •     US
    
    
    •     Canada
    
    
    
    
  
  
  •  South America
  
  
  
  


• 
  Europe
  
  
  
  • 
     Western Europe
    
    
    
    •   Germany
    
    
    •     France
    
    
    •   Italy
    
    
    •   Spain
    
    
    •   UK
    
    
    •   Rest of Western Europe
    
    
    
    
  
  
  •  Eastern Europe
  
  
  
  


• 
  Asia Pacific
  
  
  
  •   Japan
  
  
  •   China
  
  
  •  India
  
  
  • Australia  
  
  
  • Republic of Korea 
  
  
  • Rest of Asia Pacific 
  
  
  
  


• 
  The Middle East & Africa
  
  
  
  •   Middle East
  
  
  •   Africa
  
  
  
  

Huntington’s Disease Treatment Market Key Players:

•        Alnylam Pharmaceuticals Inc


•        AmpliPhi Biosciences Corp


•        Ceregene Inc


•        Lundbeck


•        Prana Biotechnology Limited


•        Teva Pharmaceutical Industries Ltd


•        Cortex Pharmaceuticals Inc


•        Vertex Pharmaceuticals Incorporated


•        Auspex Pharmaceuticals


•        SOM Biotech


•        GlaxoSmithKline


•        Siena Biotech


•        Raptor Pharmaceutical


•        Pfizer


•        Palobiofarma


•        Omeros


•        Ipsen


•        Valeant Pharmaceuticals International Inc

Recent Development

The major players, such as Neurocrine Bioscience, Inc. and Azevan Pharmaceuticals, Inc. are concentrating on research and improvement of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an innovative drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a medicine that does its work by blocking vasopressin 1 a receptor in the brain. However, presently approved medicines give symptomatic and palliative care and do not target the fundamental cause of the disease. In addition, medications can reduce the seriousness of symptoms, they are often connected with unfavorable effects such as somnolence, gait issues, dysphagia, and apathy, which can have adverse impacts on a patient’s quality of life. Given the inefficiency of a cure for the disease, it is censorious to evaluate how health-related quality of life is affected in these patients.Intended Audience:

• Manufacturers and Suppliers


• Hospitals and Clinics


• Laboratories and Associations


• Research and Development (R&D) Companies


• Government research institutes


• Academic institutes and universities